Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

Hypoxia may enhance hair growth by stimulating stem cells, but it could also risk fibrosis. Some users humorously discuss extreme methods like choking while using minoxidil, highlighting the need for new treatments.

The conversation discusses the use of Medicube Deoxyribose Gel for hair loss, with skepticism about its effectiveness due to lack of human trials. The original poster uses a combination of minoxidil, finasteride, dutasteride, RU58841, GHK-CU, and is considering adding deoxyribose gel and ketoconazole.

The conversation humorously discusses hair loss treatments, mentioning "oral miraclegro," "topical roundup," "spectracide," "Cow Dung mesotherapy," and "weekly Foot stepping sessions." The user jokingly considers switching to "weed and feed" as a treatment.

A 28-year-old male experiencing early male pattern baldness is considering using Pyrilutamide (KX-826) as an alternative to finasteride due to side effects. He seeks to maintain his current hair without regrowth and is concerned about potential side effects like reduced libido.

The conversation discusses hair loss treatment using finasteride, minoxidil chews, 0.5 dermarolling, 2% ketoconazole, and a silk bonnet. The user reports positive progress and plans to continue the regimen.

A female with PCOS and androgenetic alopecia is starting treatment with oral Minoxidil, topical Minoxidil 5% with finasteride, and plans to add mesotherapy. She previously tried anti-androgenic contraceptive pills but couldn't tolerate them and is using Myo Inositol for weight management.

The user has been using 1.25 mg finasteride and 2.5 mg oral minoxidil for 8 months, stopping topical minoxidil and dermastamping after 5 months due to exams, with no side effects reported. They are considering whether to restart topical minoxidil for additional regrowth.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

Piroctone olamine may be more effective and gentler than ketoconazole for dandruff and itchiness. Users report better results with piroctone olamine, but it is less available in the US.

Liposomal carriers for topical finasteride offer better targeting, reduced side effects, and less irritation compared to alcohol-based solutions, but availability and cost may limit their use. Minoxidil can dissolve in liposomal carriers, enhancing delivery and stability.

The user is using oral and topical minoxidil, along with dutasteride, ketoconazole shampoo, fish oil, pumpkin seed oil, B complex, and other treatments, seeking better hair regrowth results. They are frustrated with the lack of substantial regrowth despite an aggressive routine and are asking for advice on using both forms of minoxidil.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

The conversation discusses whether to continue or stop oral minoxidil for hair maintenance, with OP using spironolactone, oral and topical minoxidil, finasteride, and ketoconazole shampoo. It is suggested that stopping oral minoxidil might not cause significant hair shedding if topical treatments continue, but oral minoxidil is generally more effective for most people.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

The conversation humorously discusses using off-label drugs like Minoxidil, finasteride, and RU58841 for hair growth. It jokes about the brain absorbing these treatments for maximum keratin production.

2-Deoxy-D-Ribose is discussed as a potential hair loss treatment, but skepticism exists due to lack of human testing. The original poster uses a combination of topical Minoxidil, oral Finasteride, topical RU58841, and other treatments, reporting some hair regrowth but not significant results.

The conversation discusses hair regrowth treatments, specifically using a combination of oral and topical minoxidil, oral and topical dutasteride, and PRP. There is skepticism about the authenticity of the results, with some users questioning the changes in hair and skin appearance.

The user experienced anxiety and heart pounding from oral minoxidil, despite its effectiveness, and switched back to topical minoxidil. After managing anxiety, they found oral minoxidil more effective, but side effects differ for each person.

Adding non-prescription topicals like alfatradiol and Zix to a standard fin/min/niz regimen may help with scalp inflammation and shedding, but their long-term effectiveness varies. Zix is recommended for reducing scalp inflammation and enhancing the effectiveness of other treatments.

Mixing clascoterone with minoxidil involves using 99% ethanol and propylene glycol. Users discuss the effectiveness and potential side effects of this DIY solution.

The user is pleased with their hair growth results after using oral minoxidil (2.5mg) for 3 months and finasteride (1mg) for 4 months, despite experiencing significant shedding initially. They prefer oral treatments over topical due to convenience and concerns about toxicity to pets.

The conversation discusses creating a customized minoxidil formulation with tretinoin, azelaic acid, and caffeine, but there are concerns about foam stabilization due to acidity. The user seeks advice on the best formulation for effective results.

The user is experiencing side effects from oral minoxidil and is considering switching to a topical solution or reducing the dose. They are also using dutasteride and are seeking advice on managing side effects and treatment alternatives.

A user discusses using a mixed solution with minoxidil 2%, hydrocortisone butyrate, and estrone in the morning, and considering adding 5% minoxidil at night. They also use Restax softgel but avoid finasteride.

A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

People are discussing the group buy and availability of KX-826 for hair loss treatment, with shipments expected around March-April. There is interest in finding more information and joining future group buys.

Oral minoxidil is generally considered safe for hair loss at low doses, with rare side effects like pericardial effusion. Most users recommend staying at or below 2.5 mg and monitoring under medical supervision.

A 26-year-old used high-dose dutasteride monotherapy for two years, reporting significant hair regrowth without side effects. The user avoided combining it with minoxidil due to cardiac risk concerns.